Curated News
By: NewsRamp Editorial Staff
November 13, 2024

Clene Reports Q3 2024 Financial Results and Updates on CNM-Au8 Programs

Reddit Discuss on RedditDiscuss on LinkedIn LinkedInDiscuss on Substack SubstackView History of this news story on GitHub Github
Source News Release

TLDR

  • Clene reported Q3 2024 financial results, showing operational improvements and potential for accelerated FDA approval, providing an advantage to investors.
  • Clene's CNM-Au8 programs target mitochondrial health and neuronal function to treat neurodegenerative diseases, demonstrating a scientific approach to disease management.
  • Clene's Phase 3 RESTORE-ALS trial and innovative therapies aim to improve treatment for neurodegenerative diseases, offering hope for patients and caregivers.
  • Clene's recent developments in ALS treatment and financial updates showcase the company's dedication to advancing healthcare, making it an exciting company to watch.

Impact - Why it Matters

This news highlights Clene's advancements in ALS treatment innovation and financial progress, showcasing the company's commitment to neurodegenerative disease research. Investors can track CLNN updates at https://ibn.fm/CLNN.

Summary

Clene (NASDAQ: CLNN) reported its Q3 2024 financial results and provided updates on its CNM-Au8 programs, including a recent FDA meeting for accelerated approval of CNM-Au8 for ALS. Key highlights also included a reverse stock split, amended debt facility, and funding round. Clene's Phase 3 RESTORE-ALS trial demonstrated commitment to ALS treatment innovation. Financially, the company ended Q3 with $14.6 million in cash.

Clene Inc., a late clinical-stage biopharmaceutical company, focuses on improving mitochondrial health to treat neurodegenerative diseases. CNM-Au8® targets mitochondrial function and reduces oxidative stress. Visit www.Clene.com for more information. For investors, news and updates on CLNN can be found at https://ibn.fm/CLNN.

Source Statement

This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Reports Q3 2024 Financial Results and Updates on CNM-Au8 Programs

blockchain registration record for the source press release.